Biotech's Confidence Is Soaring. Its Workforce Tells a Different Story.
Biopharma's confidence index just hit 96 out of 100, fueled by record M&A and a dealmaking frenzy that could top $170 billion this year. But underneath the optimism, a growing chasm between large pharma's steady hiring and small biotech's skeleton crews tells a very different story.
The Vibes Are Immaculate. The Paychecks? Not So Much.
Imagine two neighbors on the same street. One just renovated the kitchen, bought a new car, and is hosting dinner parties every weekend. The other is quietly skipping meals and hoping the landlord doesn't notice the late rent.
That's biopharma in Q2 2026.
The Biopharma Sentiment Index (BPSI), a quarterly confidence survey of industry executives and investors published by Endpoints News, just hit 92 out of 100. That's up from 90 in Q1, 78 in Q4 2025, and represents the strongest reading since the post-pandemic downturn. By the numbers, the mood has never been better.
But Endpoints itself offered a telling caveat: the outlook is "murkier than the numbers suggest." The gap between the haves and have-nots in this industry is widening fast, and the clearest fault line runs straight through the job market.
The M&A Machine Is Running Hot
Let's start with the good news, because there's plenty of it. Biopharma dealmaking in 2026 is on a pace that would make a Wall Street banker weep tears of joy.
Q1 alone saw roughly $40 to $47 billion in announced M&A (the range depends on which tracker you use and how they count contingent payments). The number of billion-dollar-plus deals is tracking at a record annualized pace, according to Stifel projections.
The biggest plays tell the story. Gilead grabbed Arcellx for approximately $7.8 billion to lock down a next-gen CAR-T therapy for multiple myeloma. Eli Lilly scooped up Centessa for $6.3 billion upfront (plus up to $1.5 billion in milestone payments) to bolster its neurology pipeline. Merck went after Terns Pharmaceuticals for $6.7 billion in cash, targeting an oral oncology asset. Novartis paid $12 billion for Avidity Biosciences and its RNA-based platform.
If the current trajectory holds, analysts project full-year 2026 deal value could reach the $140–160 billion range, dwarfing 2025's approximately $133 billion and potentially challenging the all-time highs from the mid-2010s megamerger era.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
So why the shopping spree? The same reason it's always the reason: patent cliffs. Big pharma is staring down more than $200 billion in revenue at risk from expiring patents, and the fastest way to plug that hole is to buy someone else's pipeline. Oncology, obesity, immunology, and cell therapy are the hottest aisles in the store.
The Hiring Chasm Nobody Talks About
Now for the neighbor skipping meals.
While billion-dollar deals grab headlines, the workforce picture underneath tells a starkly different story. Biopharma layoff rounds rose 16% year-over-year in 2025, while the number of employees affected surged 47%, hitting an estimated 42,700 across more than 180 companies.
The recovery, such as it is, looks completely different depending on where you sit.
Large pharma is hiring again, cautiously. Companies like Lilly, Merck, and Novartis still post roles in regulatory affairs, clinical operations, manufacturing, and AI/data. Their layoff rates are projected to stay below 5% in 2026. It's not a hiring boom, but it's stable. Think of it like a company that trimmed some fat and is now selectively restocking the fridge.
Small and mid-size biotechs are in a different universe. When a biotech misses a clinical milestone or can't close a financing round, it's "not unusual to lay off 80% of its staff," according to industry workforce analysis. Many smaller companies have frozen hiring entirely, relying on skeleton crews supplemented by contractors and CROs. Entry-level roles have all but vanished at firms under pressure. The few openings that exist skew heavily toward experienced specialists willing to work on contract.
This isn't just a temporary blip. It's a structural shift. Large pharma is increasingly outsourcing work to CROs and offshore teams rather than building big internal organizations. Smaller biotechs, meanwhile, are running so lean that a single failed trial can mean clearing out the entire office. The middle ground (stable employment at a growing mid-cap biotech) is getting thinner by the quarter.
Capital: Flowing Freely, but Only for the Chosen
The funding picture reinforces this divide. Q1 2026 biotech IPOs raised $1.7 billion, the best quarterly haul since 2021.
Sounds great, right? Zoom in.
Of the 24 disclosed equity rounds from June 2025 through May 2026, 23 of 24 were above $50 million, and 12 hit $100 million or more. Capital is concentrating in fewer, bigger bets on companies with late-stage data and clear regulatory paths. If you're a preclinical biotech with a cool platform but no clinical proof, the path to going public has become exceedingly narrow.
Investors describe 2026 as a "barbell market." Strong companies with differentiated data can raise massive rounds and command premium valuations. Everyone else faces down-rounds with investor-friendly terms, forced partnerships, or outright asset sales. The IPO window is technically open, but it's more like a doggy door: only certain breeds can fit through.
This selectivity is the warning sign hiding inside the rosy BPSI score. Sentiment surveys capture the mood of people who are doing well. They don't always reflect the hundreds of companies quietly running out of cash with fewer than 12 months of runway and no clear path to their next milestone.
The Warning Signs Worth Watching
Beyond the hiring and funding divide, a few other yellow flags are fluttering:
Regulatory unpredictability. FDA staffing shortages and shifting policy frameworks (including ongoing Medicare drug pricing negotiations) continue to create uncertainty. IQVIA has flagged a "less predictable FDA" as a persistent overhang.
Confidence vs. conviction. The BPSI survey found that many insiders, despite their optimism, still wouldn't bet their own money on biopharma over the S&P 500. That's a telling gap between professional sentiment and personal conviction.
The macro overhang. Tariff concerns and broader geopolitical tensions have eased somewhat in 2026, but they haven't disappeared. Policy risk around drug pricing and China-related supply chain issues remain unresolved.
What This Actually Means
Biopharma in Q2 2026 is like a city where the penthouses are getting renovated while the ground floors flood. The top of the industry (large pharma with strong balance sheets, late-stage biotechs with validated assets) is thriving. Record M&A, rising confidence, capital flowing to quality programs.
But the foundation is uneven. Thousands of talented scientists and drug developers are still displaced from the 2023-2025 layoff waves. Small biotechs are stretching every dollar, cutting programs, and hoping their data reads out before the cash runs dry. The recovery experts are forecasting won't arrive broadly until late 2026 at the earliest, and for earlier-stage companies, possibly not until 2027.
A sentiment score of 92 feels good. But sentiment isn't reality; it's a forecast dressed in optimism. The real test for biopharma isn't whether executives feel confident. It's whether that confidence trickles down to the hundreds of companies and thousands of workers still waiting for the tide to rise.
Clinical & Regulatory
4 min read
The First Pill That Stops COVID Before It Starts
The FDA just approved the first oral antiviral that prevents COVID after exposure, not just treats it. Shionogi's Xocova cut symptomatic infection by 67% in a pivotal trial, filling a gap that's been wide open since Omicron killed off the antibody options.
